March 30, 2026 Sweden
Direkt Studios: Interim readout from Phase 3
Diamyd Medical’s CEO Ulf Hannelius and board member, Professor Mark Atkinson, comment on the interim readout from the Phase 3 study.
Produced in collaboration with Direkt Studios and moderated by Christian Ploog.
Information presented here are not press releases and may include excerpts from and links to externally published content. Diamyd Medical is not responsible for externally published content.